Table of Contents Author Guidelines Submit a Manuscript
Autoimmune Diseases
Volume 2012, Article ID 784364, 13 pages
http://dx.doi.org/10.1155/2012/784364
Review Article

Cost-Effectiveness of Multiple Sclerosis Disease-Modifying Therapies: A Systematic Review of the Literature

1Department of Health Systems, Management, and Policy, Colorado School of Public Health, 13001 E 17th Place, Aurora, CO 80045, USA
2Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA

Received 10 August 2012; Accepted 31 October 2012

Academic Editor: Giovanni Savettieri

Copyright © 2012 David Yamamoto and Jonathan D. Campbell. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [18 citations]

The following is the list of published articles that have cited the current article.

  • Elzbieta Miller, Anna Walczak, Ireneusz Majsterek, and Jozef Kedziora, “Melatonin reduces oxidative stress in the erythrocytes of multiple sclerosis patients with secondary progressive clinical course,” Journal Of Neuroimmunology, vol. 257, no. 1-2, pp. 97–101, 2013. View at Publisher · View at Google Scholar
  • Miller, Wachowicz, and Majsterek, “Advances in antioxidative therapy of multiple sclerosis,” Current Medicinal Chemistry, vol. 20, no. 37, pp. 4720–4730, 2013. View at Publisher · View at Google Scholar
  • Bernhard Haslinger, Bernhard Hemmer, Florian Castrop, and Dorothea Buck, “Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta,” Neuropsychiatric Disease And Treatment, vol. 9, pp. 1339–1349, 2013. View at Publisher · View at Google Scholar
  • Helene Parise, Patrick Lefebvre, Edward Kim, Bianca Weinstock-Guttman, Francois Laliberte, Mei Sheng Duh, Neetu Agashivala, and Safiya Abouzaid, “Direct and indirect cost burden associated with multiple sclerosis relapses: Excess costs of persons with MS and their spouse caregivers,” Journal Of The Neurological Sciences, vol. 330, no. 1-2, pp. 71–77, 2013. View at Publisher · View at Google Scholar
  • Shien Guo, Christopher Pelligra, Catherine Saint-Laurent Thibault, Luis Hernandez, and Anuraag Kansal, “Cost-Effectiveness Analyses in Multiple Sclerosis: A Review of Modelling Approaches,” Pharmacoeconomics, vol. 32, no. 6, pp. 559–572, 2014. View at Publisher · View at Google Scholar
  • Josep Darbà, Lisette Kaskens, and Rainel Sánchez-De La Rosa, “Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study,” Journal of Medical Economics, vol. 17, no. 3, pp. 215–222, 2014. View at Publisher · View at Google Scholar
  • Jonathan D. Campbell, Victoria Porter, Kavita Nair, Vahram Ghushchyan, Brett McQueen, Sharon Cahoon-Metzger, Terrie Livingston, Timothy Vollmer, John Corboy, Augusto Miravalle, and Teri Schreiner, “Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates,” Multiple Sclerosis and Related Disorders, vol. 3, no. 2, pp. 227–236, 2014. View at Publisher · View at Google Scholar
  • Michael G. Fehlings, Anick Nater, and Haley Holmer, “Cost-effectiveness of surgery in the management of metastatic epidural spinal cord compression: A systematic review,” Spine, vol. 39, no. 22, pp. S99–S105, 2014. View at Publisher · View at Google Scholar
  • Felicity Allen, Stephen Montgomery, Maciej Maruszczak, Jeanette Kusel, and Nicholas Adlard, “Convergence yet Continued Complexity: A Systematic Review and Critique of Health Economic Models of Relapsing-Remitting Multiple Sclerosis in the Unit,” Value In Health, vol. 18, no. 6, pp. 925–938, 2015. View at Publisher · View at Google Scholar
  • Daniel M. Hartung, Dennis N. Bourdette, Sharia M. Ahmed, and Ruth H. Whitham, “The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?,” Neurology, vol. 84, no. 21, pp. 2185–2192, 2015. View at Publisher · View at Google Scholar
  • Clayton English, and Joseph J. Aloi, “New FDA-approved disease-modifying therapies for multiple sclerosis,” Clinical Therapeutics, vol. 37, no. 4, pp. 691–715, 2015. View at Publisher · View at Google Scholar
  • Gj Melendez-Torres, Peter Auguste, Xavier Armoiry, Hendramoorthy Maheswaran, Rachel Court, Jason Madan, Alan Kan, Stephanie Lin, Carl Counsell, Jacoby Patterson, Jeremy Rodrigues, Olga Ciccarelli, Hannah Fraser, and Aileen Clarke, “Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation,” Health Technology Assessment, vol. 21, no. 52, pp. 1–352, 2017. View at Publisher · View at Google Scholar
  • Daniel M. Hartung, “Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA,” Neurotherapeutics, vol. 14, no. 4, pp. 1018–1026, 2017. View at Publisher · View at Google Scholar
  • Luis Hernandez, Malinda O’Donnell, and Maarten Postma, “Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations,” PharmacoEconomics, 2018. View at Publisher · View at Google Scholar
  • Jing Chen, Bruce V Taylor, Leigh Blizzard, Steve Simpson Jr, Andrew J Palmer, and Ingrid A F van der Mei, “Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 89, no. 11, pp. 1200–1207, 2018. View at Publisher · View at Google Scholar
  • Ange-Christelle Iliza, Sergio Iannazzo, and Louise Perrault, “Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies,” PharmacoEconomics, vol. 36, no. 2, pp. 189–204, 2018. View at Publisher · View at Google Scholar
  • Evelyn Walter, Thomas Berger, Barbara Bajer-Kornek, and Florian Deisenhammer, “Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria,” Journal of Medical Economics, pp. 1–19, 2018. View at Publisher · View at Google Scholar
  • Elizabeth Brouwer, Jeffrey A. Tice, Matt Seidner, Anne M. Loos, Josh J. Carlson, Marita Zimmermann, Shanshan Liu, Richard H. Chapman, and Varun Kumar, “Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis,” CNS Drugs, 2018. View at Publisher · View at Google Scholar